Intercos Europe S.p.A – FDA 483, Mar 15, 2024
An FDA inspection of Intercos Europe S.p.A, an OTC drug manufacturer in Agrate Brianza, Italy, revealed significant deficiencies in quality control and manufacturing practices. Observations included inadequate testing of components, lack of scientific justification for sampling methods, and incomplete investigations into microbiological excursions and batch record discrepancies. The firm also failed to maintain complete laboratory records and adequately document equipment cleaning procedures, with one observation being a repeat finding from a previous inspection.
ID · dca1ae64-c7cb-47a4-9946-984afd4d107f
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.